Johnson & Johnson für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 853260 / ISIN: US4781601046

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Orderbuch	Analysen
Historisch

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Orderbuch
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Johnson & Johnson

03:00		Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS (EN, Johnson & Johnson)
31.10.25		Johnson & Johnson submits application to U.S. FDA for STELARA® (ustekinumab) in the treatment of pediatric ulcerative colitis (EN, Johnson & Johnson)
29.10.25		Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting (EN, Johnson & Johnson)
28.10.25		Johnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare (EN, Johnson & Johnson)
27.10.25		JNJ Studies Show Positive Impact Of TREMFYA In Crohn's Disease Patients (RTTNews)
27.10.25		Johnson & Johnson Reports Positive Phase 2b Results For Icotrokinra In Ulcerative Colitis (RTTNews)
27.10.25		Johnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare (EN, Johnson & Johnson)
27.10.25		New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile (EN, Johnson & Johnson)
27.10.25		TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years (EN, Johnson & Johnson)
27.10.25		Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis (EN, Johnson & Johnson)
25.10.25		Johnson & Johnson's Nipocalimab Shows Promise In Reducing Sjögren's Disease Severity (RTTNews)
25.10.25		Published in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies (EN, Johnson & Johnson)
24.10.25		Johnson & Johnson Reports Strong 52-Week Data For Oral Psoriasis Drug Icotrokinra (RTTNews)
24.10.25		Johnson & Johnson MedTech Highlights Newest Impella Heart Pump and Long-Term Survival Data at TCT 2025 (EN, Johnson & Johnson)
24.10.25		Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis (EN, Johnson & Johnson)
20.10.25		Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) plus cetrelimab delivers strong pre-surgical results in patients with muscle invasive bladder cancer scheduled for radical cystectomy (EN, Johnson & Johnson)
19.10.25		Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer (EN, Johnson & Johnson)
16.10.25		TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care (EN, Johnson & Johnson)
15.10.25		Johnson & Johnson enters new era in solid tumors at ESMO 2025 with promising data across multiple cancer types (EN, Johnson & Johnson)
14.10.25		Johnson & Johnson Backs FY25 Earnings View, Lifts Sales Forecast After Q3 Beats Market - Update (RTTNews)
14.10.25		Johnson & Johnson Plans To Separate Orthopaedics Unit; Names Namal Nawana Worldwide President (RTTNews)
14.10.25		Johnson & Johnson Q3 Profit Increases, Beats Estimates (RTTNews)
14.10.25		Johnson & Johnson announces intent to separate its Orthopaedics business (EN, Johnson & Johnson)
14.10.25		Johnson & Johnson reports Q3 2025 results; raises 2025 sales outlook (EN, Johnson & Johnson)
13.10.25		Johnson & Johnson Launches INHANCE INTACT™: A Total Shoulder Replacement System Designed for Tissue-Sparing Surgery Providing Day-One Post-Op Mobility (EN, Johnson & Johnson)
10.10.25		Johnson & Johnson Initiates CORE-VA Registry to Advance Ventricular Arrhythmia Ablation Care* (EN, Johnson & Johnson)
10.10.25		Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress (EN, Johnson & Johnson)
08.10.25		U.S. FDA approves SIMPONI® (golimumab) for the treatment of pediatric ulcerative colitis (EN, Johnson & Johnson)
07.10.25		Johnson & Johnson Hit With $966 Mln Verdict In Talc Lawsuit (RTTNews)
07.10.25		Johnson & Johnson Reports Positive Phase 2b Results For Icotrokinra In Ulcerative Colitis (RTTNews)
07.10.25		Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill (EN, Johnson & Johnson)
07.10.25		TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis (EN, Johnson & Johnson)
07.10.25		Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses (EN, Johnson & Johnson)
29.09.25		U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor (EN, Johnson & Johnson)
29.09.25		J&J: FDA Approves TREMFYA For Treatment Of Pediatric Plaque Psoriasis And Active Psoriatic Arthritis (RTTNews)
24.09.25		The Johnson & Johnson Foundation Announces $5 Million Expanded Investment in Africa Frontline First Catalytic Fund to Strengthen the Community Health Workforce (EN, Johnson & Johnson)
22.09.25		Johnson & Johnson’s investigational seltorexant shows numerically higher response in patients with depression with insomnia symptoms, with fewer side effects compared to quetiapine XR (EN, Johnson & Johnson)
20.09.25		Johnson & Johnson's TREMFYA Gains FDA Nod For SC Induction In Ulcerative Colitis (RTTNews)
19.09.25		TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen (EN, Johnson & Johnson)
19.09.25		Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG) (EN, Johnson & Johnson)
19.09.25		TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma (EN, Johnson & Johnson)
19.09.25		JNJ Says TECVAYLI And DARZALEX FASPRO Demonstrated Meaningful Clinical Efficacy In Multiple Myeloma (RTTNews)
17.09.25		J&J's Icotrokinra Shows Superiority Over Deucravacitinib In Phase 3 ICONIC-ADVANCE Studies (RTTNews)
17.09.25		Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis (EN, Johnson & Johnson)
15.09.25		Johnson & Johnson Announces Launch of its Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter in Europe to Transform Treatment of Difficult-to-Cross Calcified Lesions (EN, Johnson & Johnson)
15.09.25		Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting (EN, Johnson & Johnson)
10.09.25		FDA Approves Johnson & Johnson's INLEXZO For BCG-Unresponsive Bladder Cancer (RTTNews)
09.09.25		U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated (EN, Johnson & Johnson)
07.09.25		Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer (EN, Johnson & Johnson)
06.09.25		RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer (EN, Johnson & Johnson)

1 | Weiter

Newssuche

Johnson & Johnson Peer Group Nachrichten

10:04		DAX 40-Wert Fresenius Medical Care (FMC) St-Aktie: So viel Gewinn hätte eine Investition in Fresenius Medical Care (FMC) St von vor 3 Jahren abgeworfen
10:04		SMI-Titel Novartis-Aktie: So viel Gewinn hätte ein Investment in Novartis von vor 3 Jahren eingebracht
10:04		DAX 40-Wert Beiersdorf-Aktie: So viel Verlust hätte ein Beiersdorf-Investment von vor einem Jahr eingebracht
10:04		DAX 40-Titel Merck-Aktie: So viel Verlust hätte ein Merck-Investment von vor 5 Jahren eingebracht
09:29		Nestlé-Aktie freundlich: Berenberg stuft hoch
09:22		Metsera-Übernahme im Blick: Pfizer verklagt Novo Nordisk wegen Gegengebots - Aktie im Plus
07:01		Ausblick: Pfizer präsentiert Quartalsergebnisse
31.10.25		Bayer-Aktie gefragt: Mögliche weitere rechtliche Schritt nach Niederlage im Fall Erickson geplant

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	03.11.2025 10:32
Kaufwert:	EUR
	Hinzufügen Speichern

Johnson & Johnson Aktie

WKN: 853260 / ISIN: US4781601046

Nachrichten zu Johnson & Johnson

Newssuche

Johnson & Johnson Peer Group Nachrichten

Meistgelesene Nachrichten